Baxter slides as Morgan Stanley trims target to $15 ahead of April 30 earnings
Baxter shares fell about 3% as investors reacted to fresh price-target cuts from Wall Street, led by a Morgan Stanley reduction to $15 from $19 while keeping an Underweight rating. The move extends a downtrend ahead of Baxter’s next earnings report scheduled for April 30, 2026.
1) What’s moving the stock
Baxter International (BAX) traded lower Monday as the stock digested renewed analyst caution, including a Morgan Stanley price-target cut to $15 from $19 while maintaining an Underweight rating. That kind of target reset tends to pressure sentiment in a stock already trading near multi-year lows, particularly when it arrives ahead of a scheduled earnings event.
2) The broader context investors are focused on
Baxter’s shares have been under sustained pressure since its February 12, 2026 results and outlook update, when investors zeroed in on weaker profitability and a cautious 2026 setup. The company is also in the middle of a finance leadership transition after announcing on March 16, 2026 that CFO Joel Grade will depart, with an interim CFO in place and Grade remaining as an advisor until April 30, 2026.
3) What to watch next
The next clear fundamental catalyst is Baxter’s earnings report on April 30, 2026, when investors will look for evidence that margins are stabilizing and that 2026 expectations are not headed lower again. Until then, incremental analyst revisions and target cuts are likely to remain the main day-to-day driver of the stock.